8-K/A
NEWCompany estimates $27 million to $35 million in wind-down costs following AlloNK discontinuation and 94% workforce reduction
8-K
Artiva Biotherapeutics Discontinues Development of AlloNK, Implements 94% Workforce Reduction, and Evaluates Strategic Alternatives
8-K
Artiva Biotherapeutics Announces Voting Results and Approval of Plan Amendment at 2026 Annual Meeting
8-K
Artiva Biotherapeutics Reports Q2 2026 Financial Results and Progress on AlloNK® Registrational Development
8-K
Artiva Biotherapeutics, Inc. Announces Date for 2026 Annual Meeting of Stockholders
8-K
Artiva Biotherapeutics Announces Executive Leadership Changes and Board Resignation
